Island Pharmaceuticals Ltd AI Stock Analysis
Want to see AU:ILA full AI Analyst Report?
Island Pharmaceuticals Ltd (ILA) AI Stock Analysis
Island Pharmaceuticals Ltd
(ASX:ILA)
The score is primarily constrained by severe operating losses, sustained cash burn, and the absence of recurring revenue. Weak technical momentum and a negative P/E further reduce the outlook, while the debt-free balance sheet provides only limited support.
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 87.35M
- Dividend Yield
- ―
- Average Volume (3M)
- 198.29K
- Price to Earnings (P/E)
- -8.2
- Beta (1Y)
- -0.71
- Revenue Growth
- ―
- EPS Growth
- -59.29%
- Country
- Australia
- Employees
- 0
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101, i...
Island Pharmaceuticals Ltd Financial Statement Overview
Summary
Severe revenue weakness, deeply negative profitability, and persistent operating and free-cash-flow deficits drive a very weak financial score. The debt-free balance sheet and increased asset base provide limited support, but ongoing cash burn and reliance on external financing remain significant risks.
Income Statement
18Very NegativeBalance Sheet
57NeutralCash Flow
26Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 118.91K | 1.25M | 11.06K | 0 |
| Gross Profit | -105.29K | -105.29K | -1.29M | -1.01M | 11.06K | 0 |
| EBITDA | -10.51M | -10.51M | 0 | -2.82M | 86.68K | 202.12K |
| Net Income | -9.84M | -9.84M | -3.92M | -2.86M | -2.83M | -2.61M |
Balance Sheet | ||||||
| Total Assets | 14.00M | 14.00M | 7.49M | 2.56M | 2.05M | 4.90M |
| Cash, Cash Equivalents and Short-Term Investments | 12.87M | 12.87M | 7.25M | 1.66M | 2.00M | 4.79M |
| Total Debt | 0 | 0 | 0 | 421.97K | 0 | 0 |
| Total Liabilities | 538.52K | 538.52K | 336.43K | 1.05M | 263.85K | 580.73K |
| Stockholders Equity | 13.46M | 13.46M | 7.16M | 1.52M | 1.79M | 4.32M |
Cash Flow | ||||||
| Free Cash Flow | -4.83M | -4.83M | -2.77M | -3.16M | -2.71M | -1.88M |
| Operating Cash Flow | -4.83M | -4.83M | -2.77M | -3.16M | -2.71M | -1.88M |
| Investing Cash Flow | -841.70K | -841.70K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 11.11M | 11.11M | 8.36M | 2.79M | -171.36K | 0 |
Island Pharmaceuticals Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ILA, the sentiment is Negative. The current price of 0.29 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.36, and below the 200-day MA of 0.39, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 40.30 is Neutral, neither overbought nor oversold. The STOCH value of 60.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ILA.
Island Pharmaceuticals Ltd Peers Comparison
Overall Rating
AU:DXB47Neutral
AU:PAR47Neutral
AU:RCE46Neutral- AU:ILA38Underperform
AU:ACW38Underperform
AU:IMM38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:DXB | 47Neutral | AUD 120.08M | -4.02 | 362.74% | ― | -22.13% | -108.82% |
| AU:PAR | 47Neutral | AUD 153.48M | -1.61 | -1189.87% | ― | 53.78% | -206.24% |
| AU:RCE | 46Neutral | AUD 111.63M | -7.14 | 84.67% | ― | ― | 42.51% |
| AU:ILA | 38Underperform | AUD 93.27M | -8.19 | -95.50% | ― | ― | -59.29% |
| AU:ACW | 38Underperform | AUD 174.14M | -9.38 | -103.42% | ― | ― | 5.88% |
| AU:IMM | 38Underperform | AUD 36.85M | -0.46 | -98.86% | ― | ― | -27.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:ILA | Island Pharmaceuticals Ltd | 0.29 | -0.23 | -43.81% | |
| AU:ACW | Actinogen Medical Limited | 0.04 | -0.01 | -18.18% | |
| AU:PAR | Paradigm Biopharmaceuticals Ltd. | 0.24 | -0.10 | -30.00% | |
| AU:IMM | Immutep Ltd | 0.03 | -0.26 | -91.07% | |
| AU:DXB | Dimerix Limited | 0.20 | -0.28 | -58.33% | |
| AU:RCE | Recce Pharmaceuticals Ltd. | 0.37 | -0.07 | -15.91% |
Island Pharmaceuticals Ltd Corporate Events
Island Advances Galidesivir Marburg Study at USAMRIID
Island Pharmaceuticals has begun scheduled surgical preparations for 22 non-human primates at USAMRIID in the United States, marking the next operational stage of its Galidesivir dose-optimisation study for Marburg virus disease. The procedures suppo...
Island Pharmaceuticals advances Galidesivir program with Ebola use, Marburg studies and expanded manufacturing
Island Pharmaceuticals reported strong progress in the September quarter on its Galidesivir program, securing government and regulatory approvals for compassionate use in Uganda’s Bundibugyo Ebola outbreak and creating a rare opportunity to gather re...
Island Pharmaceuticals Sets In-Person AGM and Pushes Paperless Communications
Island Pharmaceuticals has called its Annual General Meeting for 24 November 2026 in Sydney, with shareholders required to attend in person as there will be no virtual access. The company is encouraging investors to lodge directed proxy votes and sub...
Island Pharmaceuticals Expands Unquoted Employee Options Pool
Island Pharmaceuticals Ltd is an ASX-listed biotechnology company focused on developing pharmaceutical products. The company uses equity-based employee incentive schemes as part of its broader capital management and talent retention strategy in the l...
Island Pharmaceuticals ramps up Galidesivir production for Ebola and Marburg programs
Island Pharmaceuticals has begun GMP manufacturing of the antiviral Galidesivir at PI Health Sciences, with the first 5kg batch due by the end of October to support an emergency-use program in Uganda amid the Bundibugyo Ebola outbreak. The drug, auth...
Island Pharmaceuticals Reschedules AGM and Updates Director Nomination Deadline
Island Pharmaceuticals Ltd has rescheduled its Annual General Meeting, reflecting routine corporate governance adjustments as it advances its antiviral drug portfolio aimed at serious viral and biosecurity threats. The AGM will now take place on 24 N...
Island Pharmaceuticals Secures Key Marburg Data to Advance Galidesivir FDA Pathway
Island Pharmaceuticals has secured a Letter of Authorisation granting access to detailed non-human primate natural history data for the Marburg-Angola virus, a key requirement for U.S. Food and Drug Administration submissions under the Animal Rule. T...
Island Pharmaceuticals files updated ASX corporate governance statement
Island Pharmaceuticals Ltd has lodged its updated corporate governance statement for the financial year ended 30 June 2026, confirming that the document is current as of that date and has been approved by the board. The statement is hosted on the com...
Island Pharmaceuticals Posts Larger Loss as Net Tangible Assets Improve in FY2026
Island Pharmaceuticals reported a sharp increase in income from ordinary activities to $559,080 for the year ended 30 June 2026, up 214.6% from the prior year, reflecting modest revenue generation in its biotech operations. Despite this, the group’s...
Island Pharmaceuticals boosts Galidesivir supply as Bundibugyo Ebola outbreak escalates
Island Pharmaceuticals has commissioned a second manufacturing campaign of GMP-grade Galidesivir with PI Health Sciences to materially expand its available drug inventory. The company expects to have around 700 to 800 treatment courses ready by the f...
Island Pharmaceuticals Sets October AGM and Board Nomination Deadline
Island Pharmaceuticals has scheduled its Annual General Meeting for 8 October 2026 in Melbourne, with the agenda to include the re-election of directors as part of its regular corporate governance cycle. The company has set 5:00 p.m. Melbourne time o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026